Atherosclerosis
Volume 205, Issue 1 , Pages 233-238 , July 2009

Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study

  • Mary H. Zhang

      Affiliations

    • University of California, San Francisco, CA, USA
    • ,
  • Christian Spies

      Affiliations

    • Department of Medicine, University of Hawaii and the Queen's Medical Center, Honolulu, HI, USA
    • ,
  • Sadia Ali

      Affiliations

    • Section of General Internal Medicine, Veterans Affairs Medical Center, San Francisco, CA, USA
    • ,
  • Alka M. Kanaya

      Affiliations

    • Department of Medicine, University of California, San Francisco, CA, USA
    • ,
  • Nelson B. Schiller

      Affiliations

    • Department of Medicine, University of California, San Francisco, CA, USA
    • ,
  • Mary A. Whooley

      Affiliations

    • Section of General Internal Medicine, Veterans Affairs Medical Center, San Francisco, CA, USA
    • Department of Medicine, University of California, San Francisco, CA, USA
    • Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
    • Corresponding Author InformationCorresponding author at: University of California, San Francisco, 4150 Clement Street (111A1), San Francisco, CA 94121, USA. Tel.: +1 415 221 4810x3386; fax: +1 415 379 5573.

Received 5 July 2008 ,Revised 14 November 2008 ,Accepted 17 November 2008.

References 

  1. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002;13:51–59
  2. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006;16:141–146
  3. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–2476
  4. Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278:2461–2468
  5. Tian L, Luo N, Klein RL, et al. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis. 2008;
  6. Vaverkova H, Karasek D, Novotny D, et al. Positive association of adiponectin with soluble vascular cell adhesion molecule sVCAM-1 levels in patients with vascular disease or dyslipidemia. Atherosclerosis. 2008;197:725–731
  7. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11:1096–1103
  8. Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115:1408–1416
  9. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737
  10. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111:747–753
  11. Wolk R, Berger P, Lennon RJ, et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007;28:292–298
  12. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114:623–629
  13. Lawlor DA, Davey Smith G, Ebrahim S, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab. 2005;90:5677–5683
  14. Steffes MW, Gross MD, Lee DH, et al. Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the Coronary Artery Risk Development in Young Adults Study. Obesity (Silver Spring). 2006;14:319–326
  15. Cavusoglu E, Ruwende C, Chopra V, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27:2300–2309
  16. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008;93:1489–1496
  17. Beattie MS, Shlipak MG, Liu H, et al. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation. 2003;107:245–250
  18. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169–176
  19. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002;106:1883–1892
  20. Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003;108:2987–2992
  21. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367
  22. Gehi AK, Ali S, Na B, et al. Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study. Arch Intern Med. 2008;168:1423–1428
  23. Rathmann W, Herder C. Adiponectin and cardiovascular mortality: evidence for “reverse epidemiology”. Horm Metab Res. 2007;39:1–2
  24. Soydinc S, Davutoglu V, Sari I. High serum levels of adiponectin improve coronary collateral development in patients with coronary artery disease. Tohoku J Exp Med. 2007;211:347–352
  25. Tsuchida A, Yamauchi T, Ito Y, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004;279:30817–30822
  26. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451
  27. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:134–141
  28. Mallamaci F, Zoccali C, Cuzzola F, et al. Adiponectin in essential hypertension. J Nephrol. 2002;15:507–511
  29. Risch L, Saely C, Hoefle G, et al. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta. 2007;376:108–113
  30. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756–1762
  31. Sattar N, Watt P, Cherry L, et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case–control study. J Clin Endocrinol Metab. 2008;93:1846–1849
  32. Zyriax BC, Algenstaedt P, Hess UF, et al. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study. Atherosclerosis. 2008;200:403–409
  33. Rathmann W, Haastert B, Herder C, et al. Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes (Lond). 2007;31:770–776
  34. von Eynatten M, Humpert PM, Bluemm A, et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis. 2008;199:123–128

PII: S0021-9150(08)00809-5

doi: 10.1016/j.atherosclerosis.2008.11.014

Atherosclerosis
Volume 205, Issue 1 , Pages 233-238 , July 2009

Article Tools

* Image Usage & Resolution